Geron reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents. The company reported revenue of $882,000. This was 215% better than the analyst estimate for ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...

Geron Co. (NASDAQ:GERN – Free Report) – Equities researchers at Leerink Partnrs dropped their Q4 2025 EPS estimates for shares of Geron in a note issued to investors on Wednesday, February 26th.

Geron (NASDAQ:GERN) Corporation reported its fourth-quarter 2024 earnings, missing analyst expectations with an EPS of -$0.04 against a forecast of -$0.03. The company also reported a significant ...

Geron (NASDAQ:GERN – Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus ...